

First reports of adverse drug reactions and drug interactions

Accepted: 30 June 2022
© Springer Nature Switzerland AG 2022

Table 1 contains an overview of first published case reports of adverse drug reactions and interactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory

agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

Table 1 First reports of adverse drug reactions or drug interactions

Drug: event	Reference
Adverse drug reactions	
Bortezomib + cyclophosphamide + dexamethasone: spontaneous bacterial peritonitis (serious)	Manzo M, et al. Spontaneous bacterial peritonitis in a patient with nonportal hypertensive ascites. <i>Ochsner J.</i> 2022;22(1):100-3
Cefazolin: urolithiasis (serious)	Wang F, et al. Cefazolin sodium pentahydrate cause urolithiasis: a case report and literature review. <i>J Surg Case Rep.</i> 2022;2022(4):rjac115
Elexacaftor/ivacaftor/tezacaftor + ivacaftor: toxic epidermal necrolysis (serious)	Mederos-Luis E, et al. Toxic epidermal necrolysis induced by cystic fibrosis transmembrane conductance regulator modulators. <i>Contact Dermatitis.</i> 2022;86(3):224-5
Levetiracetam + pregabalin: pellagra (serious)	Boileau M, et al. Increased risk of pellagra in an alcoholic patient treated with antiepileptic drugs. <i>Ann Dermatol Venereol.</i> 2022. doi: 10.1016/j.annder.2022.03.005
Levofloxacin: symmetric drug-related intertriginous and flexural exanthema	Tsai YW, et al. Levofloxacin-induced symmetric drug-related intertriginous and flexural exanthema. <i>Contact Dermatitis.</i> 2022;86(1):64-6
Loratadine: cystoid macular oedema (serious)	Tang Y, et al. Loratadine-associated cystoid macular edema: a case report. <i>Am J Ophthalmol Case Rep.</i> 2022;26:101477
Mepolizumab: hepatic cancer (serious)	Pilette C, et al. International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A [abstract]. <i>Eur Respir J.</i> 2021;58 (Suppl 65):PA3539
Moxifloxacin: black hairy tongue (serious)	Kato M, et al. Case of moxifloxacin-induced black hairy tongue. <i>Am J Case Rep.</i> 2022;23:e936235
Romidepsin: sterile suppurative folliculitis (serious)	Sanchez-Velazquez A, et al. Romidepsin-induced sterile folliculitis in a patient with Sezary syndrome. <i>Int J Dermatol.</i> 2022;61(4):e152-4
Unspecified COVID-19 vaccine: melioidosis following reactivation of <i>Burkholderia pseudomallei</i> infection (serious)	Mohanty S, et al. Post-COVID-19 vaccination shoulder abscess and pleuroparenchymal pulmonary lesion due to <i>Burkholderia pseudomallei</i> . <i>IDCases.</i> 2022;27:e01457
Ustekinumab: acquired haemophilia A (serious)	Castralli HA, et al. Hemophilia acquired after treatment of psoriasis with ustekinumab: case report [abstract]. <i>Hematol Transfus Cell Ther.</i> 2021;43(Suppl 1):S226
Drug/supplement interactions	
Dasatinib + <i>tribulus terrestris</i> : loss of efficacy ^a (serious)	Silva GS, et al. Pharmacists role in the multi professional healthcare team - a case report of therapeutic failure due to possible drug interaction and inadequate storage of the drug in a patient with chronic myeloid leukaemia [Portuguese]. <i>Hematol Transfus Cell Ther.</i> 2021;43(Suppl 1):S459

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage

^aPoor storage conditions (high temperatures) also contributed to loss of efficacy